Aratana Therapeutics
1901 Olathe Boulevard
Kansas City
Kansas
66103
United States
Tel: 913-951-2130
Website: http://www.aratanatherapeutics.com/
183 articles about Aratana Therapeutics
-
Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.
-
Elanco Finalizes Acquisition of Aratana Therapeutics
7/18/2019
Elanco Animal Health Incorporated, finalized the acquisition of Aratana Therapeutics, a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, and developer of the first-of-its-kind canine NSAID for osteoarthritis, Galliprant®.
-
Aratana Therapeutics' Stockholders Adopt Merger Agreement with Elanco Animal Health
7/16/2019
Aratana Reports Voting Results from 2019 Special Meeting of Stockholders
-
Aratana Therapeutics Granted FDA Approval of NOCITA® (bupivacaine liposome injectable suspension) 10 mL Vial
6/11/2019
Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the U.S. Food and Drug Administration's Center for Veterinary Medicine (CVM) approved an additional vial size (10 mL) for NOCITA® (bupivacaine liposome injectable suspension)
-
Aratana Therapeutics Reports Voting Results from 2019 Annual Meeting of Stockholders
6/7/2019
Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting results for the four proposals considered and voted upon by its stockholders at its Annual Meeting on June 6, 2019.
-
Aratana Therapeutics Reports First Quarter 2019 Financial Results
5/8/2019
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, announced its first quarter 2019 financial results and recent business highlights
-
Aratana Therapeutics to Present at Stifel 2019 Dental & Veterinary Conference
5/7/2019
Aratana Therapeutics, Inc., a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, plans on presenting at the Stifel Dental & Veterinary Conference on Wednesday, May 29, 2019 at 8:00 a.m. ET in New York City.
-
Aratana Therapeutics to be Acquired by Elanco Animal Health
4/26/2019
Elanco announces formation of commercial team dedicated to veterinary specialty business
-
Aratana Therapeutics to Report First Quarter 2019 Financial Results
4/22/2019
A replay of the first quarter 2019 results teleconference will be available the same day of the event and an audio webcast will be accessible for 90 days in the Aratana Investor Room.
-
Aratana Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
3/12/2019
Aratana Therapeutics, Inc., a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, announced its fourth quarter and full year 2018 financial results and recent business highlights.
-
Aratana Therapeutics to Participate at Upcoming Investment Conferences
2/13/2019
Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, plans on attending the following upcoming investment conferences:
-
Aratana Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results
2/12/2019
Aratana Therapeutics, Inc. will host a live conference call on Tuesday, March 12, 2019 at 4:30 p.m. ET to discuss financial results from the fourth quarter and full year ended December 31, 2018.
-
BioSpace Movers and Shakers: Feb. 8
2/8/2019
In this week's edition of Movers and Shakers, biopharma companies tap executives to serve in various leadership roles. -
Aratana Therapeutics Appoints Rhonda Hellums Chief Financial Officer
2/4/2019
Aratana Therapeutics, Inc. today announced the appointment of Rhonda Hellums as Chief Financial Officer and Treasurer of Aratana effective February 1, 2019.
-
Aratana Therapeutics' Board of Directors Appoints Craig Tooman Chief Executive Officer
1/18/2019
Aratana Therapeutics, Inc. announced the Company's Board of Directors has appointed Craig Tooman to serve as President and Chief Executive Officer of Aratana, and elected Tooman to the Board of Directors.
-
Aratana Therapeutics Reports Third Quarter 2018 Financial Results
11/1/2018
Aratana Therapeutics, Inc. announced its third quarter 2018 financial results.
-
Aratana Therapeutics to Report Third Quarter 2018 Financial Results
10/22/2018
Aratana Therapeutics is a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats
-
Aratana Therapeutics Reports Second Quarter 2018 Financial Results
8/2/2018
Aratana Therapeutics, Inc. announced its second quarter 2018 financial results.
-
Aratana Therapeutics Files for FDA Approval of NOCITA® (bupivacaine liposome injectable suspension) Label Expansion
6/1/2018
The filing is intended to expand the NOCITA label to include its use in cats as a peripheral nerve block to provide regional post-operative analgesia following onychectomy.
-
Aratana Therapeutics Appoints Craig Barbarosh and Lowell Robinson to its Board of Directors in Cooperation Agreement with Engaged Capital
5/21/2018
Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, today announced the Company has appointed Craig Barbarosh and Lowell Robinson to its Board of Directors (Board) in connection with a cooperation agreement with Engaged Capital, LLC ("Engaged Capital").